ライフサイエンスコーパス: Taxus

1 taxane C-10 hydroxyl acetyl transferase from Taxus.

2 nsion cultures of members of the plant genus Taxus.

3 sels were randomly assigned 3:2 to CoStar or Taxus.

4 1,675 (98.5%) were evaluable (CoStar = 989; Taxus = 686), including 1,330 (79%) single-vessel and 34

5 10-O-acetyltransferase along with five other Taxus acyltransferases on the paclitaxel (Taxol) biosynt

6 The baseline Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score (bSS) from 2,68

7 low to intermediate Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score (random-effects

8 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Score is an objective

9 ween Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score of 32 or lower

10 as assessed by the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score.

11 ween Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial demonstrated th

12 ween Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial is a multicente

13 ween percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) trial is the most imp

14 The Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial was a non-infer

15 LM patients in the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) trial, the largest tr

16 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery [SYNTAX]; NCT00114972).

17 (SYNergy Between PCI With TAXus and Cardiac Surgery [SYNTAX]; NCT00114972).

18 (Synergy Between PCI With Taxus and Cardiac Surgery [SYNTAX]; NCT00114972; Evaluat

19 TO in the SYNTAXES (Synergy Between PCI With Taxus and Cardiac Surgery Extended Survival) study, whic

20 is of the SYNTAXES (Synergy Between PCI With Taxus and Cardiac Surgery Extended Survival) study, whic

21 rs in the SYNTAXES (Synergy between PCI with Taxus and Cardiac Surgery Extended Survival) trial.

22 The baseline Synergy Between PCI With Taxus and Cardiac Surgery score was similar between grou

23 ercutaneous coronary intervention (PCI) with TAXUS and Cardiac Surgery trial, 1800 patients with 3-ve

24 CABG in the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) (enrollment period 2005 to 20

25 mized SYNTAX trial (Synergy Between PCI With Taxus and Cardiac Surgery) comparing PCI with CABG in pa

26 e SYNTAX score (SS; Synergy Between PCI With TAXUS and Cardiac Surgery) in choosing between percutane

27 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score (SS), a measure of anat

28 tion of the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score has prompted a renewed

29 P<0.0001), SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score of >/=11 (the sample me

30 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score quantifies the extent o

31 nd the mean SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score was 19.7 +/- 9.6.

32 d diabetes, SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score, treatment of saphenous

33 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) scores and lesion characteris

34 BCIS-JS and SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) scores were 8 (Q1-Q3: 6-10) a

35 ween percutaneous coronary intervention with Taxus and cardiac surgery) scores were measured using co

36 ween percutaneous coronary intervention with TAXus and cardiac surgery) study randomly assigned 1,800

37 lity in the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) trial, beyond its original 5-

38 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial, patients with 3-vessel

39 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial, the effect of treatmen

40 randomized SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) trial.

41 omes of the SYNTAX (SYNergy Between PCI With TAXUS and Cardiac Surgery) trial.

42 ween Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial.

43 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery), an assessment of anatomic co

44 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery), and residual Jeopardy Score

45 (Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival [SYN

46 ded Survival study (Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival [SYN

47 (Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival [SYN

48 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; I and II), which were present

49 m 4 trials (SYNTAX [Synergy Between PCI With Taxus and Cardiac Surgery], PRECOMBAT [Premier of Random

50 similar in the 2 groups, 16.4% and 22.5% in TAXUS and control, respectively (P=0.12), including comp

51 ercutaneous coronary intervention (PCI) With Taxus and coronary artery bypass surgery (CABG)] score i

52 The TAXUS ATLAS study is a global, prospective, single-arm t

53 Using Taxus baccata, a conifer species without resin, we devel

54 her (Cordis Corp., Miami Lakes, Florida) and Taxus (Boston Scientific Corp., Natick, Massachusetts) D

55 r the Cypher (Cordis, Miami, Florida) or the Taxus (Boston Scientific, Maple Grove, Minnesota) stent

56 Johnson & Johnson, Warren, New Jersey], 17% Taxus [Boston Scientific, Maple Grove, Minnesota]).

57 CI [percutaneous coronary intervention] with TAXUS [Boston Scientific] and Cardiac Surgery) score was

58 akes, Florida) and paclitaxel-eluting stent (TAXUS, Boston Scientific Corp., Natick, Massachusetts) w

59 SES, n = 69), and paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, Massachusetts) (PES, n

60 tent anticancer drug first isolated from the Taxus brevifolia Pacific yew tree.

61 ted with recombinant taxadiene synthase from Taxus brevifolia to elucidate the stereochemistry of the

62 ep of Taxol biosynthesis in the Pacific yew (Taxus brevifolia) is the cyclization of the linear isopr

63 urified taxadiene synthase from Pacific yew (Taxus brevifolia) stems to examine the possibility of a

64 rom poly(A)+ RNA extracted from Pacific yew (Taxus brevifolia) stems.

65 lex diterpene obtained from the Pacific yew, Taxus brevifolia, is arguably the most important new dru

66 on, a library was made from the stem bark of Taxus brevifolia.

67 grandis and taxadiene synthase (C(20)) from Taxus brevifolia], all of which are involved in natural

68 nt geranylgeranyl diphosphate synthases from Taxus canadensis and Abies grandis yielded a functional

69 A Taxus canadensis phenylalanine aminomutase (TcPAM) catal

70 The phenylalanine aminomutase from Taxus catalyzes the vicinal exchange of the amino group

71 cytochrome P450 oxygenases led to the use of Taxus cell cultures induced for Taxol production and the

72 mRNA isolated from methyl jasmonate-induced Taxus cells, from which several full-length acyltransfer

73 mRNA isolated from methyl jasmonate-induced Taxus cells, from which the full-length 10-deacetylbacca

74 cal to the recombinant enzyme and clone from Taxus chinensis, acquired recently by a reverse genetics

75 with the enzymes, depending upon the type of Taxus cultivars used.

76 ariety of taxane in extracts of a variety of Taxus cultivars were converted to a 10-deacetylbaccatin

77 ammonia lyase-like sequence acquired from a Taxus cuspidata cDNA library was expressed functionally

78 om sequencing of a cDNA library derived from Taxus cuspidata cells (induced for taxoid biosynthesis w

79 library constructed from mRNA isolated from Taxus cuspidata cells induced for Taxol production with

80 library (constructed from mRNA isolated from Taxus cuspidata cells induced with methyl jasmonate for

81 III:10beta-O-acetyltransferase isolated from Taxus cuspidata regiospecifically transfers short-chain

82 -O-benzoyltransferase has been isolated from Taxus cuspidata.

83 biosynthetic pathway, has been isolated from Taxus cuspidata.

84 xol) biosynthetic pathway and one additional Taxus-derived acyltransferases of unknown function were

85 s, Menlo Park, California) with those of the Taxus DES (Boston Scientific, Maple Grove, Minnesota) in

86 The CoStar DES is not noninferior to the Taxus DES based on per-patient clinical and per-vessel a

87 The Cypher and Taxus DES result in delayed arterial healing when compar

88 Cypher and Taxus DES showed greater delayed healing characterized b

89 Late stent thrombosis (LST) after Cypher and Taxus drug-eluting stent placement has emerged as a majo

90 vival [SYNTAXES], NCT03417050; SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass S

91 (TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass S

92 diabetes, 3-vessel disease, or high SYNTAX (TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass S

93 dure according to definitions of the SYNTAX (TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass S

94 vival [SYNTAXES]; NCT03417050; SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass S

95 Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Co

96 e arterial reaction to overlapping Cypher or Taxus drug-eluting stents was examined in rabbits with b

97 (3:1), controlled, multicenter study of the TAXUS Element (vs. TAXUS Express) PES for the treatment

98 The TAXUS Element is a novel thin-strut (81 microm), platinu

99 At 1 year, the TAXUS Element is comparable in efficacy to the TAXUS Exp

100 of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System f

101 of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System)

102 and efficacy of the novel platinum chromium TAXUS Element paclitaxel-eluting stent (PES) compared wi

103 A prespecified analysis was conducted of the Taxus Element vs Xience Prime in a Diabetic Population (

104 The TAXUS Element was noninferior to TAXUS Express with resp

105 luded 1,262 patients (320 TAXUS Express, 942 TAXUS Element).

106 y artery bypass graft surgery [CABG]) versus TAXUS Express (Boston Scientific, Natick, Massachusetts)

107 nia) everolimus-eluting stent (EES) with the TAXUS Express (Boston Scientific, Natick, Massachusetts)

108 t is non-inferiority of TAXUS Liberte versus TAXUS Express for 9-month target vessel revascularizatio

109 was powered to demonstrate noninferiority to TAXUS Express for both end points.

110 ours of symptom onset were randomized 3:1 to TAXUS EXPRESS paclitaxel-eluting stents (PES) or EXPRESS

111 3-vessel disease to receive either PCI (with TAXUS Express paclitaxel-eluting stents) or CABG.

112 p is an entry-criteria-matched population of TAXUS Express patients from the TAXUS IV and V trials.

113 itaxel-eluting stent (PES) compared with the TAXUS Express PES (Boston Scientific, Natick, Massachuse

114 XUS Element is comparable in efficacy to the TAXUS Express PES.

115 fic Corp., Natick, Massachusetts) versus the TAXUS Express stent (Boston Scientific Corp.).

116 The TAXUS Element was noninferior to TAXUS Express with respect to both the incidence of targ

117 multicenter study of the TAXUS Element (vs. TAXUS Express) PES for the treatment of de novo coronary

118 -treat analysis included 1,262 patients (320 TAXUS Express, 942 TAXUS Element).

119 rating that TAXUS Liberte is non-inferior to TAXUS Express.

120 ficantly more complex for TAXUS Liberte than TAXUS Express.

121 were randomized (1:1) between a drug-eluting TAXUS Express2 and an uncoated Express2 control stent.

122 Patients receiving Taxus Express2 drug-eluting stents experienced a 1.28-fo

123 onfirmed increased risk following use of the Taxus Express2 stent but not the Angio-Seal STS device.

124 monstrates that six previously characterized Taxus genes can coordinatively produce key paclitaxel in

125 ow-up, IVUS lumen volumes were larger in the TAXUS group (123 +/- 43 mm(3) vs. 104 +/- 44 mm(3), p =

126 ears there were more stent thromboses in the Taxus group (hazard ratio 0.19 [95% confidence interval

127 hrombosis occurred in 1.28% +/- 0.31% in the Taxus group and 0.76% +/- 0.23% in the bare-metal stent

128 get-vessel revascularization was 9.1% in the TAXUS group and 19.4% in the control group (P=0.0027; re

129 s or IVUS parameters between the control and TAXUS groups.

130 Yew trees (Taxus) hyperbranch from long-lived buds that lie underne

131 ase using a single pAclitaXel elUting Stent [TAXUS]-I, -II, -IV, and -VI) (RR = 1.01, 95% CI 0.40 to

132 The relative benefit of Taxus is primarily attributable to reduction in TVR.

133 opulation of TAXUS Express patients from the TAXUS IV and V trials.

134 al restenosis rates from both the Pacitaxil (TAXUS IV) and Sirolimus (SIRIUS) drug eluting stents sug

135 TAXUS IV, V, and VI were double-blind, randomized, multi

136 erial intravascular ultrasound substudies of TAXUS IV, V, and VI.

137 Unique identifiers: TAXUS IV: NCT00292474; TAXUS V: NCT00301522; TAXUS VI: N

138 2.53, p = 0.99), trials with longer lesions (TAXUS-IV and -VI) (RR = 0.62, 95% CI 0.2 to 1.91, p = 0.

139 follow-up on revascularization rates in the TAXUS-IV trial and to determine whether the relative ben

140 The TAXUS-IV trial demonstrated that the slow-release, polym

141 The TAXUS-IV trial demonstrated the safety and effectiveness

142 In the TAXUS-IV trial, 1,314 patients were prospectively random

143 In the TAXUS-IV trial, 1,314 patients with single de novo coron

144 In the TAXUS-IV trial, 1,314 patients with stable or unstable i

145 In the TAXUS-IV trial, 1,314 percutaneous coronary intervention

146 In the TAXUS-IV trial, 1314 patients with single de novo corona

147 Using the angiographic substudy of the TAXUS-IV trial, in which 1,314 patients with de novo cor

148 In the TAXUS-IV trial, patients were randomized to the slow-rel

149 In the TAXUS-IV trial, treatment with PES led to substantial re

150 either PES (N = 662) or BMS (N = 652) in the TAXUS-IV trial.

151 nt in Patients with Coronary Artery Disease (TAXUS-IV) trial because of the high incidence of silent

152 th De Novo Coronary Artery Lesions (SIRIUS), TAXUS-IV, and the First and Second First Use to Undersco

153 Within Taxus' large, enzyme-rich genome(5), we suspected that t

154 rimary end point was met, demonstrating that TAXUS Liberte is non-inferior to TAXUS Express.

155 y (TL-PAS) contributed patients treated with TAXUS Liberte paclitaxel-eluting stent and prasugrel to

156 or 30 months reduced ischemic events for the TAXUS Liberte paclitaxel-eluting stent patient subset fr

157 al antiplatelet therapy with prasugrel after TAXUS Liberte paclitaxel-eluting stent remains unknown,

158 proven TAXUS technology to the more advanced TAXUS Liberte platform was demonstrated.

159 The TAXUS Liberte Post Approval Study (TL-PAS) contributed p

160 ssess non-inferiority of the next-generation TAXUS Liberte stent (Boston Scientific Corp., Natick, Ma

161 ntly lower in-stent LLL at 6 months than the Taxus Liberte stent did, with a trend toward better 12-m

162 patients enrolled, 162 received Cre8 and 161 Taxus Liberte stents.

163 esions were randomly assigned 1:1 to Cre8 or Taxus Liberte stents.

164 eristics were significantly more complex for TAXUS Liberte than TAXUS Express.

165 The primary end point is non-inferiority of TAXUS Liberte versus TAXUS Express for 9-month target ve

166 TAXUS Liberte was designed to combine the established po

167 permanent-polymer paclitaxel-eluting stents (Taxus Liberte, Boston Scientific, Natick, Massachusetts)

168 e the treatment of more complex lesions with TAXUS Liberte, the primary end point was met, demonstrat

169 e P450 enzyme [taxane oxetanase 1 (TOT1)] in Taxus mairei that catalyzes an oxidative rearrangement i

170 We used cultivated Taxus media trees for analyses of the chemical compositi

171 ical pathways underlying PTX biosynthesis in Taxus media.

172 ng clinical and angiographic outcomes of the TAXUS Moderate Release paclitaxel-eluting stent in the t

173 The finding that the TAXUS Moderate Release stent system is safe and effectiv

174 els comparable with the natural abundance in Taxus needles.

175 oss was 0.49 mm with CoStar and 0.18 mm with Taxus (p < 0.0001).

176 months was 11.0% for CoStar versus 6.9% for Taxus (p < 0.005), including adjudicated death (0.5% vs.

177 tents, there was a significant increase with Taxus (P=0.03).

178 om 32.9% in the control group to 9.1% in the TAXUS patients (P<0.0001).

179 were available in 170 patients, including 88 TAXUS patients and 82 controls, at implantation and at n

180 Approximately 0.8% of Taxus patients have stent thrombosis in the first 6 mont

181 The Taxus phenylalanine aminomutase (PAM) enzyme converts se

182 hylidene imidazolone (NH(2)-MIO) adduct of a Taxus phenylalanine aminomutase.

183 aclitaxel:N-benzoyltransferase (NDTBT), from Taxus plants, transfers a benzoyl group from the corresp

184 chanistically similar aminomutase TcPAM from Taxus plants.

185 nt-based meta-analysis using the 4 principal TAXUS randomized trials (3,445 patients) with a follow-u

186 from a stent coated with biostable polymer (Taxus) reduces restenosis after PCI.

187 No Taxus-related stent thrombosis occurred after 2 years (9

188 Of 8 patients with Taxus-related thrombosis after 6 months, 0 were taking c

189 While Taxus sp. cell suspension cultures have displayed the cr

190 e genomic and transcriptomic information for Taxus species to identify cytochrome P450 candidates and

191 ame Taxol), which is derived from yew trees (Taxus species)(3).

192 Taxus stem barks can be used for extraction of paclitaxe

193 was reduced among patients randomized to the TAXUS stent (2.6% vs. 6.3%, p = 0.02).

194 re similar in men and women treated with the TAXUS stent (8.6% vs. 7.6%, respectively, p = 0.80), as

195 restenosis in women was randomization to the TAXUS stent (OR = 0.28 [95% CI 0.11 to 0.74], p = 0.01).

196 sel revascularization rate was 7.9% with the TAXUS stent and 18.6% with the bare-metal stent (p = 0.0

197 between the two groups, and reduced with the TAXUS stent at the distal edge (p = 0.004).

198 w-release, polymer-based, paclitaxel-eluting TAXUS stent compared to bare-metal stents in patients un

199 By actuarial analysis, the TAXUS stent compared with the bare-metal stent reduced t

200 hs for the polymer-based, paclitaxel-eluting TAXUS stent compared with the EXPRESS stent is preserved

201 ients per 6 months) were similar between the Taxus stent group (0.59 [95% confidence interval 0.22 to

202 t surgery due to restenosis is reduced after TAXUS stent implantation in LAD lesions.

203 mpared to control stents, treatment with the TAXUS stent in women resulted in a significant reduction

204 w-release, polymer-based, paclitaxel-eluting TAXUS stent or a bare-metal EXPRESS stent (Boston Scient

205 w-release, polymer-based, paclitaxel-eluting TAXUS stent or a bare-metal EXPRESS stent (Boston Scient

206 w-release, polymer-based, paclitaxel-eluting TAXUS stent or an identical bare-metal stent; 536 (41%)

207 w-release, polymer-based, paclitaxel-eluting TAXUS stent or an identical-appearing bare-metal EXPRESS

208 ate-release polymer-based paclitaxel-eluting TAXUS stent or the bare-metal EXPRESS stent (Boston Scie

209 randomized to either the paclitaxel-eluting TAXUS stent or to its bare-metal equivalent, we defined

210 In the insulin-requiring subgroup, the TAXUS stent reduced angiographic restenosis by 82% (7.7%

211 n 2.5- to 3.75-mm vessels were randomized to TAXUS stent versus bare-metal EXPRESS stents (Boston Sci

212 The use of the paclitaxel-eluting TAXUS stent was safe in patients with unstable ischemic

213 s (including 187 women) were assigned to the TAXUS stent, and 652 (180 women) received the control st

214 Among patients with diabetes, the TAXUS stent, compared to the bare-metal stent, reduced t

215 Among patients receiving the TAXUS stent, women compared with men had higher unadjust

216 stent thrombosis with the paclitaxel-eluting Taxus stent.

217 observed in only 3.0% of control and 4.0% of TAXUS stents (p = 0.12).

218 Polymer-based, paclitaxel-eluting TAXUS stents are effective in inhibiting neointimal tiss

219 r, a modest increase in risk is present with Taxus stents beyond 6 months, possibly because of inadeq

220 Taxus stents induced greater fibrin deposition, medial c

221 Overlapped segments in Taxus stents induced significantly more luminal heteroph

222 The successful transfer of the proven TAXUS technology to the more advanced TAXUS Liberte plat

223 stablished polymer-based, paclitaxel-elution TAXUS technology with the more advanced Liberte stent pl

224 e cardiac events (MACE) occurred in 13.5% of TAXUS-treated patients versus 21.2% treated with the con

225 Unique identifiers: TAXUS IV: NCT00292474; TAXUS V: NCT00301522; TAXUS VI: NCT00297804.

226 TAXUS VI is a prospective, multicenter, double-blind, ra

227 TAXUS IV: NCT00292474; TAXUS V: NCT00301522; TAXUS VI: NCT00297804.

228 ilable transcriptome data sets obtained with Taxus x media.

229 differential display-cloning approach, using Taxus (yew) cells induced for Taxol production, yielded